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Introduction
HIV infection leads to worse treatment outcomes in visceral leishmaniasis (VL) and increases
the risk of post-treatment relapse, suggesting that similar effects may be observed in other low
CD4+ T cell states [1]. Idiopathic CD4+ T cell lymphocytopenia (ICL) was first described in
1992 in the setting of the emerging HIV pandemic [2]. It is a rare condition defined as a CD4+
T cell count persistently <300 cells/μl in the absence of known secondary causes of lymphope-
nia, such as HIV infection [3]. VL infection in individuals with ICL is a little-reported clinical
entity [4, 5, 6] and here we report in detail our experiences of 2 such patients from the Hospital
for Tropical Diseases (HTD). The cases discussed here add an important clinical perspective to
the immunological models. One patient has had complex refractory disease managed over the
last 12 years, developing both ocular and dermal leishmaniasis and demonstrating how CD4
deficiency without HIV infection affects the clinical course of VL.
Presentation of Case 1
A 53-year-old British male with known psoriasis and chronic kidney disease (CKD) presented
to his general practitioner (GP) in August 2004 with fatigue, night sweats, weight loss, and
exertional breathlessness. He lived in the United Kingdom and his lifetime travel history to
Leishmania-endemic areas consisted of Spain in 2002, Cyprus annually from 1998–2003, and,
in June 2004 (2 months prior to presentation), a 2-week holiday to the Greek island of
Zakynthos, during which he reported insect bites. He was investigated and found to have pan-
cytopenia, and in October 2004, Leishmania amastigotes were identified on a bone marrow
biopsy, giving the patient a diagnosis of VL. Polymerase chain reaction (PCR) testing detected
Leishmania donovani DNA. In November 2004, the patient had his first course of treatment
with intravenous (IV) AmBisome (liposomal amphotericin B), leading to a resolution of his
symptoms.
In February 2005, the patient relapsed for the first time with recurrence of his presenting
symptoms and was treated empirically with a further course of IV AmBisome. Following his
second relapse in June 2005, the patient was referred to the HTD for management. Relapse
was confirmed with a bone marrow biopsy showing Leishmania amastigotes, and in July 2005,
the patient had his third treatment course, consisting of oral miltefosine and IV AmBisome.
Between August 2005 and June 2008, the patient was managed with prophylactic IV pent-
amidine isethionate infusions once every 2 weeks and had a relapse-free period. In January
2006, the patient developed bilateral anterior uveitis and intraocular hypertension of unknown
etiology. This was managed with systemic immunosuppression, intraocular steroid injections,
and, in 2008, bilateral ocular surgical drainage.
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In June 2008, the patient presented with 6 months of new, small, tender, raised erythema-
tous skin lesions over his abdomen and legs, distinct from the non-tender psoriatic patches on
his elbows. Numerous Leishmania amastigotes were identified on skin biopsy of a lesion, giv-
ing the patient a diagnosis of Post-kala-azar dermal leishmaniasis (PKDL) and representing
his third clinical relapse. In July 2008, Leishmania organisms or DNA were not identified on
microscopy and PCR of a splenic aspirate, showing that the patient had not had a systemic
recurrence of VL. The patient was not treated at this time.
The patient’s vision continued to deteriorate despite aggressive treatment of his anterior
uveitis and intraocular hypertension, and he was registered as blind in April 2009. In May
2009, the patient underwent an ocular vitreous aspirate to determine if his visual deterioration
could be related to his leishmaniasis. Leishmania species DNA was identified on PCR of the
aspirate, confirming intraocular leishmaniasis and his fourth clinical relapse. In July 2009, the
patient was admitted for treatment with 28 days of IV sodium stibogluconate. After 22 days,
the course was halted due to drug toxicity. A repeat biopsy of a skin lesion at this time did not
identify Leishmania on microscopy or PCR, and so stibogluconate treatment was not contin-
ued. Leishmania DNA was not identified on PCR of a further ocular vitreous aspirate in Octo-
ber 2009.
Between October 2009 and May 2010, the patient remained off prophylactic pentamidine,
which was stopped prior to admission and not restarted following discharge. In May 2010, the
patient had a fifth clinical relapse. Leishmania amastigotes were visualized on microscopy of a
bone marrow biopsy at this time, and Leishmania donovani complex DNA was identified on
PCR of the sample. The patient was treated with a further course of IV AmBisome in June
2010. A splenic aspirate in July 2010 found no Leishmania amastigotes on microscopy, but
Leishmania DNA continued to be isolated on PCR of the sample. At this time, the patient was
re-commenced on prophylactic pentamidine infusions administered once every 3 weeks. In
March 2011, Leishmania DNA was once again isolated from PCR of an ocular vitreous aspi-
rate, but a splenic aspirate at this time did not identify Leishmania organisms or DNA, indicat-
ing that the pentamidine infusions were controlling his systemic infection but not the ocular
disease.
In August 2011, the patient presented to clinic with new erythematous papular lesions on
his abdomen. Skin slit smear microscopy of these revealed amastigotes, confirming further
dermal leishmaniasis and his sixth relapse. Leishmania DNA was identified on PCR of a
splenic aspirate in April 2012, and the patient was managed with a further course of oral milte-
fosine and IV AmBisome.
During this time, a cause was sought for the patient’s treatment refractory disease. HIV
serology was negative and immunoglobulins were within normal range. Lymphocyte subset
analysis, consisting of total lymphocyte count, CD3+ lymphocyte count (T cell count),
CD3+CD4+ lymphocyte count (helper or CD4+ T cell count), and CD3+CD8+ lymphocyte
count (cytotoxic or CD8+ T cell count), was undertaken on multiple occasions during the
course of the patient’s illness and revealed a persistently low CD4+ T cell count of between
40–160 cells/μl along with a low CD8+ T cell count of 180–220 cells/μl. Investigations for sec-
ondary causes of his persistent lymphopenia were non-diagnostic. There was no history of
malnutrition, alcohol excess, radiotherapy, recent surgery, inflammatory bowel disease, or
immunosuppressive medication other than intermittent systemic and local corticosteroid
treatment for his anterior uveitis and intraocular hypertension. Multiple blood films, bone
marrow biopsies, and splenic aspirates found no evidence of hematological malignancy, and
cross-sectional imaging did not demonstrate any solid organ malignancies. Screening for auto-
immune diseases and sarcoidosis was negative, and cardiac and renal function were grossly
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normal. When no known secondary cause of lymphopenia could be identified after extensive
investigation, the patient was given a diagnosis of ICL.
In August 2012, a post-treatment skin biopsy of a PKDL skin lesion showed mild chronic
inflammation only, with no evidence of Leishmania on microscopy or PCR, suggesting the
patient had cleared the Leishmania from his skin. Since this time, his leishmaniasis has been
kept in remission by ongoing three-weekly pentamidine prophylaxis, and he has remained
relapse-free.
Presentation of Case 2
A 42-year-old Serbian male with type 2 diabetes mellitus presented on July 2014 with fevers,
drenching night sweats, weight loss, and fatigue. The patient was born in Belgrade, Serbia, and
had been living in the UK since 2011. Lifetime travel history to Leishmania-endemic regions
included holidays to Gibraltar in 2008, Spain in 2011, and Greece in 2013.
Widespread lymphadenopathy and hepatosplenomegaly was found on cross-sectional
imaging, and the patient was referred to the HTD with a suspected diagnosis of VL. Leish-
mania serology by direct agglutination test (DAT) was strongly positive at a titre of 1:102,400
(a titre exceeding 1:1,600 is considered positive). Leishmania amastigotes were subsequently
identified on a lymph node biopsy, confirming the diagnosis of VL, although PCR was unable
to confirm the species. The patient was treated with a course of IV AmBisome.
Due to our experiences with the patient from Case 1, HIV testing and lymphocyte subsets
are now requested as baseline investigations for all patients with VL managed at the HTD, and
the patient from Case 2 underwent these tests accordingly. HIV serology was negative, but
lymphocyte subset analysis revealed a persistently low CD4+ T cell count of 90–160 cells/μl,
with normal CD8+ T cell levels. As with the patient from Case 1, no secondary causes of his
persistent lymphopenia could be identified, giving the patient a diagnosis of ICL.
The patient had a good clinical response to a single course of treatment with IV AmBisome
and remains in remission since 2014, without prophylaxis. We continue to monitor him for
relapses.
Case discussion
Leishmania infection is controlled in the host by a T cell–mediated immune response, with
CD4+, CD8+, and natural killer T cells contributing to the immunological processes involved
[7]. CD4+ T cells are thought to play a major role, with animal models of VL suggesting that
CD4+ T cells are responsible for organ-specific antiparasitic immunity, immune surveillance,
and parasite suppression [8, 9]. Additionally, certain cytokines have emerged as having key
pathogenic or protective roles in VL. Interleukin 10 (IL-10), produced by dendritic cells (DCs)
and regulatory T cells (Tr1), acts to suppress antiparasitic immune mechanisms in human VL,
with IL-10 deficiency protecting against infection and blockade of IL-10 signaling, enhancing
antiparasitic immunity [7, 8]. Conversely, interferon gamma (IFNγ) appears crucial for host
control of the disease, with elevated levels correlating with recovery, and neutralization of
IFNγ in vitro promoting parasite growth [7, 10]. The main source of IFNγ production in the
context of VL is CD4+ Th1 cells, which are in turn induced by DC interleukin 12 (IL-12) pro-
duction [8, 10]. Deficiency of CD4+ T cells would thus be expected to result in reduced IFNγ
production and impaired ability of the host to control infection.
The cases discussed here add a clinical perspective to the immunological models, suggesting
that patients with ICL are predisposed to developing chronic VL following exposure and have
reduced ability to clear Leishmania parasites, leading to relapse despite treatment. The patient
from Case 2 responded successfully to a single course of treatment. In contrast, the patient
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from Case 1, who had a lower nadir CD4+ T cell count, a low CD8+ T cell count, and received
concurrent steroid therapy, had complex treatment refractory disease with multiple relapses,
including ocular and dermal disease, and is held in remission by long-term pentamidine pro-
phylaxis. This suggests that these factors may have had a cumulative deleterious effect on the
clinical course of his disease.
It has been our experience at the HTD that immunodeficiency is a risk factor for the devel-
opment of VL, with two-thirds of the VL patients we see having some form of immunodefi-
ciency identified [11]. Given that AmBisome treatment has a 95% cure rate [12], patients who
relapse following treatment should be investigated for underlying immunodeficiency. We sug-
gest that, where available, both HIV testing and lymphocyte subset analysis should be consid-
ered as baseline investigations for all patients diagnosed with VL—adopting this strategy, we
have thus far identified 2 patients with underlying ICL. Additionally, in patients who relapse
following treatment, in whom baseline HIV testing is negative and lymphocyte subset analysis
is normal, these tests should be repeated and other causes of immunodeficiency sought and
corrected where possible, such as immunosuppressive medications, environmental toxins,
malnutrition, alcohol excess, malignancy, organ failure, protein-losing disorders, and meta-
bolic and endocrine disorders.
Patients with VL and any form of immunodeficiency, such as ICL or immunosuppressive
therapy, must be monitored closely for signs of relapse and may benefit from secondary pro-
phylaxis, which has been found to be effective in preventing relapse in immunocompromised
patients [4]. IFNγ therapy has had some success in treatment of other infections in the context
of ICL and so may have a future therapeutic role in the management of VL infection in
patients with ICL [13, 14].
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